register

News & Trends - Pharmaceuticals

Lundbeck to cut R&D workforce

Health Industry Hub | June 10, 2020 |

Pharma News – As part of its Expand and Invest to Grow-strategy, Lundbeck plans to make changes to its organisation in Research & Development (R&D). The initiative could lead to a reduction of around 130-160 employees.

Lundbeck plans to optimise its R&D-organisation to enhance the company’s ability to strengthen and advance its pipeline across all phases in an evolving neuroscience landscape.

“The proposed changes will allow us to fully execute on our strategy in the years to come and rebuild our pipeline with innovative programs with strong potential to deliver highly impactful treatments for patients with brain disorders. Through this we will support Lundbeck in becoming the premier neuroscience company, globally” says Johan Luthman, Executive Vice President, R&D at Lundbeck.

Earlier this year, Lundbeck’s migraine prevention drug Vyepti (eptinezumab) was approved by the FDA. Teva, Eli Lilly and Amgen/Novartis already have calcitonin gene-related peptide (CGRP) class migraine drugs on the market, but Lundbeck is hoping to differentiate itself from the competition with an intravenous formulation taken in a clinic instead of self-injected with a pen.

While there are hopes that Vyepti could generate blockbuster-level revenues, the company still relies on several mental health drugs for its revenue, which have been on the market for several years and face generic competition.

With the cut in R&D workforce, Lundbeck also plans to expand the company’s operating space and rebuild its pipeline of potential new medicines to treat brain disorders.


Human Resources

The return-to-office debate: Where are we in the pendulum's swing?

The return-to-office debate: Where are we in the pendulum’s swing?

Health Industry Hub | May 24, 2024 |

People & Culture: The evolution of hybrid and flexible workplaces has yielded mixed results across the healthcare sector, with some […]

More


News & Trends - MedTech & Diagnostics

Cardinal Health launches local facility for reprocessing of single-use medical devices

Cardinal Health launches local facility for reprocessing of single-use medical devices

Health Industry Hub | May 24, 2024 |

MedTech & Diagnostics News: Cardinal Health is set to launch a cutting-edge facility in Australia dedicated to the reprocessing of […]

More


Medical

New ophthalmic centre to partner on pharma and medtech clinical trials

New ophthalmic centre to partner on pharma and medtech clinical trials

Health Industry Hub | May 24, 2024 |

Medical: The Victorian Deputy Premier and Minister for Medical Research, the Hon Ben Carroll, has launched a cutting-edge ophthalmic clinical […]

More


News & Trends - Pharmaceuticals

Private sector, government and academia gather to tackle barriers in vaccine value chain

Private sector, government and academia gather to tackle barriers in vaccine value chain

Health Industry Hub | May 24, 2024 |

Pharma News: An ‘invite only’ vaccine thought leadership event, aimed at addressing gaps in Australia’s vaccine ecosystem and maximising the […]

More


This content is copyright protected. Please subscribe to gain access.